Saquinavir + RTV versus Lopinavir-RTV in Treatment-Naïve GEMINI Trial
Saquinavir + RTV versus Lopinavir-RTV in Treatment Naïve

GEMINI: Study Design

Study Design: GEMINI

- **Background**: Randomized, open-label, non-inferiority, phase III trial comparing the safety and efficacy of saquinavir plus ritonavir with lopinavir-ritonavir, both with tenofovir DF-emtricitabine, in treatment-naïve patients with HIV infection

- **Inclusion Criteria** (n = 337)
  - Age ≥18
  - Antiretroviral-naïve
  - CD4 count ≤350 cells/mm³
  - HIV RNA >10,000 copies/mL

- **Treatment Arms**
  - Saquinavir 1000 mg BID + ritonavir 100 mg BID + TDF-FTC QD
  - Lopinavir-ritonavir (400-100) BID + TDF-FTC QD

Saquinavir + RTV versus Lopinavir-RTV in Treatment Naïve 
GEMINI: Results

Week 48: Virologic Response (ITT, Missing=Failure)

Saquinavir + RTV versus Lopinavir-RTV in Treatment Naïve
GEMINI: Results

Week 48: Analysis of Lipids

Conclusions: “In treatment-naive, HIV-1-infected patients, SQV/r treatment was noninferior in virologic suppression at 48 weeks to LPV/r treatment and offered a better triglyceride profile.”
The **National HIV Curriculum** is an AIDS Education and Training Center (AETC) Program resource funded by the United States Health Resources and Services Administration. The project is led by the University of Washington and the AETC National Coordinating Resource Center.

*The content in this slide set does not represent the official views of the U.S. Department of Health and Human Services, Health Resources & Services Administration.*